Israel - hebraico - Ministry of Health

trima israel pharmaceutical products maabarot ltd - dimetindene maleate - ג'ל - dimetindene maleate 0.1 %w/w - dimetindene

Israel - hebraico - Ministry of Health

trima israel pharmaceutical products maabarot ltd - aluminium chlorohydrate; undecenoic acid; zinc undecenoate - אבקה - undecenoic acid 3 g / 100 g; aluminium chlorohydrate 3 g / 100 g; zinc undecenoate 18 g / 100 g - other antifungals for topical use - for prophylaxis and treatment of fungal infections of the skin especially "athletes foot".

Israel - hebraico - Ministry of Health

pharmalogic ltd - methotrexate 10 mg/ml - solution for injection - methotrexate - antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. palliation of acute lymphocytic leukemia. in the treatment and prophylaxis of meningeal leukemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. in combination with other anticancer agents, methotrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. methotrexate is effective in the treatment of the advanced stages (iii and iv peter's staging system) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. psoriasis: because of the high risk attending its use, methotrexate is indicated only in the

Israel - hebraico - Ministry of Health

teva pharmaceutical industries ltd, israel - solifenacin succinate - טבליה - solifenacin succinate 5 mg - solifenacin - solifenacin - solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Israel - hebraico - Ministry of Health

teva pharmaceutical industries ltd, israel - solifenacin succinate - טבליה - solifenacin succinate 10 mg - solifenacin - solifenacin - solifenacin is indicated for symptomatic treatment of urge incontinence and/or urinary frequency and urgency as may occur in patients with overactive bladder syndrome.

Israel - hebraico - Ministry of Health

novartis pharma services ag - phentolamine mesylate 10 mg/ml - solution for injection - phentolamine - 1. management of hypertensive crises which may occur in patients with phaeochromocytoma e.g. during pre-operative preparation and surgical intervention. 2. diagnosis of phaeochromocytoma by the regitine test if other specific tests are not available.

Israel - hebraico - Ministry of Health

pharmalogic ltd - oxytocin - תמיסה להזרקה\אינפוזיה - oxytocin 10 iu/ml - oxytocin - induction of labour for medical reasons stimulation of labour in hypotonic uterine inertia during caesarian section following the delivery ot the child prevention and treatment of postpartum uterine atony and haemorrhage.oxytocin injection may also be indicated in early stages of pregnancy as an adjunctive therapy for the management of incomplete inevitable or missed abortion.

Israel - hebraico - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 104 mg / 0.65 ml - medroxyprogesterone - medroxyprogesterone - * sayana is indicated for long-term female contraception. each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). however, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year .since loss of bone mineral density may occur in females of all ages who use sayana long-term, a risk/benefit assessment, which also takes into consideration the decrease in bone mineral density that occurs during pregnancy and/or lactation, should be considered.* use in adolescents (12-18 years)in adolescents, use of sayana is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with sayana during the critical period of bone accretion.sayana has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate in this population.

Israel - hebraico - Ministry of Health

astellas pharma international b.v., israel - mirabegron - טבליות בשחרור ממושך - mirabegron 25 mg - mirabegron

Israel - hebraico - Ministry of Health

astellas pharma international b.v., israel - mirabegron - טבליות בשחרור ממושך - mirabegron 25 mg - mirabegron